Last quarter (Q2 2022), CSPC Pharmaceutical Group's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, CSPC Pharmaceutical Group's net income was ¥―. See CSPC Pharmaceutical Group’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	¥ 27.87B	¥ 24.94B	¥ 22.10B	¥ 17.72B	¥ 12.92B
Cost of Revenue	-	¥ 6.73B	¥ 6.26B	¥ 6.19B	¥ 5.98B	¥ 5.11B
Gross Profit	-	¥ 21.14B	¥ 18.69B	¥ 15.91B	¥ 11.74B	¥ 7.81B
Operating Expense	-	¥ 14.34B	¥ 12.63B	¥ 11.31B	¥ 7.91B	¥ 4.90B
Operating Income	-	¥ 6.79B	¥ 6.06B	¥ 4.60B	¥ 3.82B	¥ 2.91B
Net Non Operating Interest Income Expense	-	¥ -7.66M	¥ -12.23M	¥ -32.43M	¥ -74.34M	¥ -22.25M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	¥ 6.85B	¥ 6.39B	¥ 4.63B	¥ 3.79B	¥ 2.90B
Tax Provision	-	¥ 1.16B	¥ 1.16B	¥ 892.81M	¥ 733.76M	¥ 572.60M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ 5.61B	¥ 5.16B	¥ 3.71B	¥ 3.08B	¥ 2.32B
Basic EPS	-	-	¥ 0.43	¥ 0.31	¥ 0.26	-
Diluted EPS	-	-	¥ 0.43	¥ 0.31	¥ 0.26	-
Basic Average Shares	-	-	¥ 11.95B	¥ 11.95B	¥ 11.98B	-
Diluted Average Shares	-	-	¥ 11.96B	¥ 11.96B	¥ 11.98B	-
Dividend Per Share	-	-	¥ 0.15	¥ 0.08	¥ 0.06	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 21.07B	¥ 18.89B	¥ 17.50B	¥ 13.89B	¥ 10.01B
Net Income From Continuing And Discontinued Operation	-	¥ 5.61B	¥ 5.16B	¥ 3.71B	¥ 3.08B	¥ 2.32B
Normalized Income	-	¥ 5.57B	¥ 4.89B	¥ 3.71B	¥ 3.08B	¥ 2.32B
Interest Expense	-	¥ 7.66M	¥ 12.23M	¥ 32.43M	¥ 74.34M	¥ 22.25M
EBIT	-	¥ 6.85B	¥ 6.40B	¥ 4.66B	¥ 3.87B	¥ 2.92B
EBITDA	-	¥ 7.72B	¥ 7.21B	¥ 5.35B	¥ 4.50B	¥ 3.52B

Currency in CNY

CSPC Pharmaceutical Group Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing